Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology
Open Access
- 1 January 2012
- journal article
- Published by Springer Science and Business Media LLC in Molecular Neurodegeneration
- Vol. 7 (1), 39
- https://doi.org/10.1186/1750-1326-7-39
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and HopesCurrent Topics in Medicinal Chemistry, 2011
- Suppression of Amyloid Deposition Leads to Long-Term Reductions in Alzheimer's Pathologies in Tg2576 MiceJournal of Neuroscience, 2009
- Dynamics of Aβ Turnover and Deposition in Different β-Amyloid Precursor Protein Transgenic Mouse Models Following γ-Secretase InhibitionThe Journal of pharmacology and experimental therapeutics, 2008
- A multigram chemical synthesis of the γ-secretase inhibitor LY411575 and its diastereoisomersBioorganic & Medicinal Chemistry Letters, 2007
- Anti-A 42- and anti-A 40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse modelJCI Insight, 2005
- Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell DifferentiationOnline Journal of Public Health Informatics, 2004
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002
- Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid depositionNeurobiology of Aging, 2001
- Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brainJournal of Neurochemistry, 2001
- Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?Cell, 1993